News
HOTH
1.170
0.00%
0.000
Weekly Report: what happened at HOTH last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at HOTH last week (0408-0412)?
Weekly Report · 04/15 11:47
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Healthcare Hoth Therapeutics files to sell 5.03M shares of common stock for holders Apr. 11, 2024 4:24 p.m. HothTherapeutics filed a prospectus related to the resale of an aggregate of 5,030,000 shares.
Seeking Alpha · 04/11 20:24
*Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Dow Jones · 04/11 20:23
Weekly Report: what happened at HOTH last week (0401-0405)?
Weekly Report · 04/08 11:53
Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating
TipRanks · 04/05 10:26
Hoth Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 04/05 10:25
Hoth Therapeutics Price Target Raised to $7.00/Share From $6.50 by EF Hutton
Dow Jones · 04/02 13:13
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Dow Jones · 04/02 13:13
EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
Benzinga · 04/02 13:03
Weekly Report: what happened at HOTH last week (0325-0329)?
Weekly Report · 04/01 11:50
Hoth Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Hoth Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 32 cents per share. The mean expectation of three analysts was for a loss of 51 cents. Reported revenue was zero; analysts expected zero; shares fell 4.2% this quarter.
Reuters · 03/31 21:02
Weekly Report: what happened at HOTH last week (0318-0322)?
Weekly Report · 03/25 11:53
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
NASDAQ · 03/20 09:38
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. Fell sharply after the company reported worse-than-expected fourth-quarter EPS results. Ontrak, Inc. Shares climbed 197.8% to $0.5660 in Tuesday's mid-day session. Fusion Pharmaceuticals Inc. Gained 97.3% after agreeing to be acquired by AstraZeneca.
Benzinga · 03/19 17:48
Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?
Hoth Therapeutics Inc (NASDAQ:HOTH) unveiled positive preclinical research showcasing the potential of HT-ALZ, an Alzheimer’s disease therapeutic. The company says the treatment reduces anxiety-like behavior and enhances cognitive function in mice. Last year in August, Hoth announced the development of a therapeutic in development for Alzheimer's Disease.
Benzinga · 03/19 17:01
Hoth stock rallies 24% on preclinical Alzheimer's data
Shares of Hoth Therapeutics rallied 24% on preclinical Alzheimer's data. The company reported positive preclinical data for its drug candidate HT-ALZ in the treatment of neuroinflammation and cognitive deficits associated with Alzheimer's disease. Hoth said it remains committed to further researching the therapy for Alzheimer's.
Seeking Alpha · 03/19 14:32
Hoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study
Shares of Hoth Therapeutics soar 32% in early trading. The company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ. Shares are now in positive territory year-to-date. The stock was up 32% at $1.52.
Dow Jones · 03/19 14:15
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.02% to 1689.96. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is +0.01% to 1378.25.
Seeking Alpha · 03/19 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. Fusion Pharmaceuticals and Enveric Biosciences moved upwards by 97.46% and 39.09% respectively. Losers include Seelos Therapeutics and Acurx Pharmaceuticals.
Benzinga · 03/19 13:05
More
Webull provides a variety of real-time HOTH stock news. You can receive the latest news about Hoth Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HOTH
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.